Investing in pharmaceuticals or biotechnology can be risky because of the unpredictability of clinical trial outcomes. In addition to the rigorous due diligence you do with the company and financial data, looking closely into the scientific data can reduce investment risk. Whether you’re a venture capitalist uncertain about data presented by companies seeking funding, or a private equity manager wanting to get a better idea of the likelihood of a public company’s drug trial success, having a statistical expert on your side can be the difference between a bad investment and a good one.
Public Company Investment
BioRankings® works with closely with hedge fund and other investors to analyze the data around a therapeutic trial to give the best estimate of trial success. We use all relevant publicly available resources, including but not limited to published papers, poster presentations, press releases, and interviews, to analyze the data that companies are using to convince you their drug/therapeutic works.
Put the same due diligence rigor behind the data surrounding the science as you do with the company and financials. BioRankings works closely with your team to ensure the best information is used in our analysis, and to promote your team’s understanding of the validity of their statistical claims.
Work performed on public company trial data includes:
Examples of past Statistical Due Diligence consultations and results
BioRankings predicted that Inhaled Remodulin would be successful before the company’s announcement.
BioRankings predicted that GPC’s Satraplatin would fail before the company’s announcement.
The BioRankings method showed the data was too close to warrant a guaranteed pass or fail for Keryx’s Sulodexide.
Venture and Angel Investment
As investors you devote significant time to IP, market, financial, and company leadership due diligence, but likely accept as true with little or no due diligence the statistical claims made by the company. Having expert statisticians review the data provided to you by a company looking for investment helps ensure that you aren’t missing something in these statistical claims that could potential sink the company later on.
BioRankings works with Venture and Angel investors to examine the statistical data around a company looking for investment’s invention. We use all clinical or pre-clinical data and plans provided by the company, along with any outside data sources that could be useful, to determine what statistical factors might be relevant to the product’s success. We work with your team and the company looking for funding to ensure that there is a strong data argument for the product and plan moving forward.